PT  - JOURNAL ARTICLE
AU  - Emmanuel, Benjamin
AU  - Biswas, Mousumi
AU  - Scott, Megan
AU  - Small, Mark
AU  - Lee, Lauren
AU  - Chen, Stephanie
AU  - Ruiz, Sandrine
TI  - Real-world evidence of reported symptoms and quality of life burden associated with chronic rhinosinusitis with nasal polyposis and comorbid asthma status
AID  - 10.1183/13993003.congress-2021.OA1590
DP  - 2021 Sep 05
TA  - European Respiratory Journal
PG  - OA1590
VI  - 58
IP  - suppl 65
4099  - http://erj.ersjournals.com/content/58/suppl_65/OA1590.short
4100  - http://erj.ersjournals.com/content/58/suppl_65/OA1590.full
SO  - Eur Respir J2021 Sep 05; 58
AB  - Introduction: Real-world assessments for symptoms and quality-of-life (QoL) associated with chronic rhinosinusitis with nasal polyposis (CRSwNP) with/without comorbid asthma are scarce.Methods: The Adelphi Real World CRSwNP Disease Specific Programme™, a cross-sectional survey of patients with bilateral moderate to severe CRSwNP and their physicians, was utilised in the US, Europe, and Japan. Physicians provided information on clinical outcomes and CRSwNP symptoms and a subset of corresponding patients completed a questionnaire (Sino-Nasal Outcome Test-22, EuroQol 5-dimension). Assessments were analysed by comorbid asthma status.Results: From 1697 CRSwNP patients, 708 (42%) were diagnosed with asthma; 521 (31%) with severe asthma; and 989 (58%) were without asthma. Patients reported higher prevalence and severity for CRSwNP symptoms vs physician reports irrespective of asthma status. Daily symptoms and severe symptom burden were reported more frequently in asthma and severe asthma patients than patients without comorbid asthma; QoL scores were lower among patients with vs without asthma (Figure). Conclusions: CRSwNP with comorbid asthma is associated with more severe symptoms and higher QoL burden. Symptoms reported by physicians are fewer compared with from patients. When assessing CRSwNP symptoms and QoL burden, a more patient-centric view needs to be taken.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, OA1590.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).